

**Highlights of This Issue 2129**

**SPECIAL FEATURES**

**CCR Drug Updates**

- 2131** Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer  
Sean Khozin, Chana Weinstock, Gideon M. Blumenthal, Joyce Cheng, Kun He, Luning Zhuang, Hong Zhao, Rosane Charlab, Ingrid Fan, Patricia Keegan, and Richard Pazdur

**Molecular Pathways**

- 2136** Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer  
Lakshmi Reddy Bollu, Abhijit Mazumdar, Michelle I. Savage, and Powel H. Brown

**Review**

- 2143** Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets  
Alexander E. Kudinov, John Karanicolas, Erica A. Golemis, and Yanis Bumber

**Clinical Trial Brief Report**

- 2154** Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia  
Preetesh Jain, Michael J. Keating, William G. Wierda, Mariela Sivina, Philip A. Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Susan O'Brien, and Jan A. Burger

**CANCER THERAPY: CLINICAL**

- 2159** FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma  
Amy K. Erbe, Wei Wang, Jacob Goldberg, Mikayla Gallenberger, KyungMann Kim, Lakeisha Carmichael, Dustin Hess, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Su-Chun Cheng, Sabina Signoretti, Michael Atkins, Alexander Carlson, James W. Mier, David J. Panka, David F. McDermott, and Paul M. Sondel

- 2169** Neoadjuvant Enzalutamide Prior to Prostatectomy  
Bruce Montgomery, Maria S. Tretiakova, Anthony M. Joshua, Martin E. Gleave, Neil Fleshner, Glenn J. Bubley, Elahe A. Mostaghel, Kim N. Chi, Daniel W. Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W. Kantoff, Brett T. Marck, Stephen Plymate, Steven P. Balk, Peter S. Nelson, Alvin M. Matsumoto, Rosina T. Lis, Adam Kibel, Gabriel P. Haas, Andrew Krivoshik, Alison Hannah, and Mary-Ellen Taplin

- 2177** The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma  
Zheng Wang, Yajing Hao, Chuanbao Zhang, Zhiliang Wang, Xing Liu, Guanzhang Li, Lihua Sun, Jingshan Liang, Jianjun Luo, Dabiao Zhou, Runsheng Chen, and Tao Jiang

- 2186** Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial  
Ravindra Uppaluri, Ashley E. Winkler, Tianxiang Lin, Jonathan H. Law, Bruce H. Haughey, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Jason A. Diaz, Loren P. Michel, Tanya Wildes, Gavin P. Dunn, Paul Zolkind, Dorina Kallogjeri, Jay F. Piccirillo, Farokh Dehdashti, Barry A. Siegel, Rebecca D. Chernock, James S. Lewis, Jr., and Douglas R. Adkins

- 2195** Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors  
Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Elisa Chiadini, Claudio Dazzi, Maximilian Papi, Laura Capelli, Claudia Casanova, Nicoletta De Luigi, Marita Mariotti, Alessandro Gamboni, Rita Chiari, Chiara Bennati, Daniele Calistri, Vienna Ludovini, Lucio Crinò, Dino Amadori, and Paola Ulivi


**PERSONALIZED MEDICINE AND IMAGING**

- 2203** Simultaneous *In Vivo* Fluorescent Markers for Perfusion, Porphyrin Metabolism, and EGFR Expression for Optically Guided Identification of Orthotopic Glioma  
Jonathan T. Elliott, Kayla Marra, Linton T. Evans, Scott C. Davis, Kimberley S. Samkoe, Joachim Feldwisch, Keith D. Paulsen, David W. Roberts, and Brian W. Pogue

# Table of Contents

- 2213** **Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer**  
James M. Flanagan, Angela Wilson, Chail Koo, Nahal Masrouf, John Gallon, Erick Loomis, Kirsty Flower, Charlotte Wilhelm-Benartzi, Alexander Hergovich, Paula Cunnea, Hami Gabra, Elena Ioana Braicu, Jalid Sehouli, Silvia Darb-Esfahani, Adriaan Vanderstichele, Ignace Vergote, Caroline Kreuzinger, Dan Cacsire Castillo-Tong, G. Bea A. Wisman, Els MJJ Berns, Nadeem Siddiqui, James Paul, and Robert Brown
- 2223** **Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses**  
Adriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, Chiara Landolfo, Els Van Nieuwenhuysen, Karin Leunen, Patrick Neven, Frédéric Amant, Sven Mahner, Elena Ioana Braicu, Robert Zeilinger, An Coosemans, Dirk Timmerman, Diether Lambrechts, and Ignace Vergote
- 2232** **Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases**  
Sydney Dubois, Pierre-Julien Vially, Elodie Bohers, Philippe Bertrand, Philippe Ruminy, Vinciane Marchand, Catherine Maingonnat, Sylvain Mareschal, Jean-Michel Picquenot, Dominique Penther, Jean-Philippe Jais, Bruno Tesson, Pauline Peyrouze, Martin Figeac, Fabienne Desmots, Thierry Fest, Corinne Haioun, Thierry Lamy, Christiane Copie-Bergman, Bettina Fabiani, Richard Delarue, Frédéric Peyrade, Marc André, Nicolas Ketterer, Karen Leroy, Gilles Salles, Thierry J. Molina, Hervé Tilly, and Fabrice Jardin
- 2245** **Structure and Function of a Prostate Cancer Dissemination–Permissive Extracellular Matrix**  
Marie-France Penet, Samata Kakkad, Arvind P. Pathak, Balaji Krishnamachary, Yelena Mironchik, Venu Raman, Meiyappan Solaiyappan, and Zaver M. Bhujwala
- 2267** **Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers**  
Qiong J. Wang, Zhiya Yu, Ken-ichi Hanada, Krishna Patel, David Kleiner, Nicholas P. Restifo, and James C. Yang
- 2277** **Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells**  
Loretta Gammaitoni, Lidia Giraudo, Marco Macagno, Valeria Leuci, Giulia Mesiano, Ramona Rotolo, Francesco Sassi, Martina Sanlorenzo, Alessandro Zaccagna, Alberto Pisacane, Rebecca Senetta, Michela Cangemi, Giulia Cattaneo, Valentina Martin, Valentina Coha, Susanna Gallo, Ymera Pignochino, Anna Sapino, Giovanni Grignani, Fabrizio Carnevale-Schianca, Massimo Aglietta, and Dario Sangiolo
- 2289** **Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia**  
Isabel Ben-Batalla, Robert Erdmann, Heather Jørgensen, Rebecca Mitchell, Thomas Ernst, Gunhild von Amsberg, Philippe Schafhausen, Janna L. Velthaus, Stephen Rankin, Richard E. Clark, Steffen Koschmieder, Alexander Schultze, Subir Mitra, Peter Vandenberghe, Tim H. Brümmendorf, Peter Carmeliet, Andreas Hochhaus, Klaus Pantel, Carsten Bokemeyer, G. Vignir Helgason, Tessa L. Holyoake, and Sonja Loges
- 2301** **Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts**  
Hung-Ming Lam, Ryan McMullin, Holly M. Nguyen, Ilsa Coleman, Michael Gormley, Roman Gulati, Lisha G. Brown, Sarah K. Holt, Weimin Li, Deborah S. Ricci, Karin Verstraeten, Shibu Thomas, Elahe A. Mostaghel, Peter S. Nelson, Robert L. Vessella, and Eva Corey
- 2313** **The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia**  
Matthew D. Blunt, Stefan Koehrer, Rachel C. Dobson, Marta Larrayoz, Sarah Wilmore, Alice Hayman, Jack Parnell, Lindsay D. Smith, Andrew Davies, Peter W.M. Johnson, Pamela B. Conley, Anjali Pandey, Jonathan C. Strefford, Freda K. Stevenson, Graham Packham, Francesco Forconi, Greg P. Coffey, Jan A. Burger, and Andrew J. Steele
- 2325** **NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability**  
Kamalakannan Palanichamy, Suman Kanji, Nicolaus Gordon, Krishnan Thirumoorthy, John R. Jacob, Kevin T. Litzenberg, Disha Patel, and Arnab Chakravarti

## CANCER THERAPY: PRECLINICAL

- 2255** **Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition**  
 Jiangtao Ren, Xiaojun Liu, Chongyun Fang, Shuguang Jiang, Carl H. June, and Yangbing Zhao

# Table of Contents

## BIOLOGY OF HUMAN TUMORS

**2335** Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculation and Metastasis

Hong-Tai Tzeng, Chung-Han Tsai, Yi-Ting Yen, Hung-Chi Cheng, Yi-Chieh Chen, Shih-Wen Pu, Yu-Shiuan Wang, Yan-Shen Shan, Yau-Lin Tseng, Wu-Chou Su, Wu-Wei Lai, Li-Wha Wu, and Yi-Ching Wang

**2346** Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 $\beta$ , IL8, CXCL5, and Mip-1 $\alpha$

Yana G. Najjar, Patricia Rayman, Xuefei Jia, Paul G. Pavicic Jr, Brian I. Rini, Charles Tannenbaum, Jennifer Ko, Samuel Haywood, Peter Cohen, Thomas Hamilton, C. Marcela Diaz-Montero, and James Finke

**2356** lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study

Paolo Martini, Lara Paracchini, Giulia Caratti, Maurizia Mello-Grand, Robert Fruscio, Luca Beltrame, Enrica Calura, Gabriele Sales, Antonella Ravaggi, Eliana Bignotti, Franco E. Odicino, Enrico Sartori, Patrizia Perego, Dionyssios Katsaros, Ilaria Craparotta, Giovanna Chiorino, Stefano Cagnin, Laura Mannarino, Lorenzo Ceppi, Costantino Mangioni, Chiara Ghimenti, Maurizio D'Incalci, Sergio Marchini, and Chiara Romualdi

**2367** Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer


William J. Gibson, Daniel T. Ruan, Vera A. Paulson, Justine A. Barletta, Glenn J. Hanna, Stefan Kraft, Antonio Calles, Matthew A. Nehs, Francis D. Moore Jr, Amaro Taylor-Weiner, Jeremiah A. Wala, Travis I. Zack, Thomas C. Lee, Fiona M. Fennessy, Erik K. Alexander, Tom Thomas, Pasi A. Janne, Levi A. Garraway, Scott L. Carter, Rameen Beroukhim, Jochen H. Lorch, and Eliezer M. Van Allen

 AC icon indicates Author Choice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows fluorescence images of ABY-029 (green), 5-ALA-induced PpIX (blue), and IRDye680RD-CX (red) tissue distribution acquired on *ex vivo* brain tissue sections bearing large F98 EGFR-positive tumors. The distribution of these imaging agents, which were acquired 3 hours following coinjection, represent markers of EGFR expression, protoporphyrin metabolism, and perfusion, respectively, which enable optically guided tumor identification. For details, see the article by Elliott and colleagues on page 2203 of this issue.



# Clinical Cancer Research

**23 (9)**

*Clin Cancer Res* 2017;23:2129-2373.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/23/9>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/9>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.